BAZA HIGH CONVICTION FUND MONTH ENDED 31 AUGUST 2022




KEY METRICS FOR MONTH

Unit price (pre fees, expenses & distribution)	A\$0.9728
Fees & expenses for month	(A\$0.0017)
Unit price post fees & expenses, pre distribution	A\$0.9712
Distribution	-
Unit price post distributions, fees & expenses	A\$0.9712
Performance in Aug-22, post fees & expenses	-2.2%
S&P/ASX Small Ords Accum. Index (Benchmark) return	+0.6%
Fund performance vs. Benchmark in Aug-22 ¹	-2.8%
Cash as at 31-Aug-22	9.2%

HISTORICAL PERFORMANCE

Value of A\$100,000 invested at inception



HISTORICAL RELATIVE PERFORMANCE

	Fund	S&P/ASX Small Ords	Relative Fund
	return ^{1,2}	Accum. Index	performance
1 month	-2.2%	+0.6%	-2.8%
3 months	-9.6%	-2.6%	-7.0%
6 months	-13.9%	-6.1%	-7.8%
12 months	-19.3%	-14.7%	-4.6%
Since inception ³	+55.7%	+4.0%	+51.7%
Since inception (annualised) ³	+19.0%	+1.6%	+17.5%

COMMENTARY

The Baza High Conviction Fund (the Fund) returned -2.2% during August, underperforming the S&P/ASX Small Ordinaries Accumulation Index (Benchmark) which rose +0.6%. August saw most global equity markets give back some of their July gains, with the NASDAQ (-4.6%) and S&P 500 (-4.2%) down, while the S&P/ASX 200 (+0.6%) posted modest gains.

14 of the Fund's largest holdings reported FY22 results in August. 12 companies reported results either in line or slightly better than market expectations. We were generally pleased with the resilience of earnings across our portfolio and expect this to continue.

Shade cloth manufacturer, Gale Pacific (GAP), exceeded guidance for FY22, despite higher transport and warehousing costs across its US business. Increases in revenue and profit are anticipated in FY23, primarily driven by growth in the Americas.

Beauty clinic operator, Silk Laser (SLA), exceeded EBITDA guidance and confirmed that demand for its products and services remains strong despite reports of wavering consumer confidence. Our expectation is that demand will prove resilient and allow Silk Laser to continue with its organic and inorganic growth objectives in FY23 and beyond.

Domestic pharmaceuticals manufacturer, Probiotec (PBP), reported strong revenues and earnings for FY22 despite difficult operating conditions driven by COVID-19, and issued strong guidance for FY23 due to increased demand for cold & flu medication.

The 2 Fund investments that posted disappointing results were Service Stream (SSM) and Symbio Holdings (SYM). SSM reported results with lower margins due in part to the recent Queensland floods, which led to delays and cost overruns for a major utility project and reduced overall utilities division earnings. We increased our position in SSM post results as we expect margins will increase back toward historic levels as exceptional conditions abate. SYM disappointed with a lack of progress against its flagged Asian expansion and escalating costs. Profitability eroded, as did our confidence in management's ability to execute on profitable growth (we promptly exited our position in SYM given the material adverse change to the company's investment case).

- 1. Post all fees and expenses
- 2. Assumes reinvestment of distributions (A\$0.023 declared 30-Jun-20 and A\$0.647 declared 30-Jun-21)
- 3. Since inception, 15-Jan-20



FUND SNAPSHOT

The Baza High Conviction Fund is a long only small-cap fund targeting undervalued emerging companies on the ASX. Actively invested in emerging companies that have the ability to generate sustainable, long-term shareholder returns. The Fund has a high risk, high return profile.

The Fund utilises strict responsible investment screening parameters; both positive and negative.

Inception	15-Jan-20
Structure	Unit trust
Management fee	1.5% p.a. (incl. GST)
Performance fee	20.0% (incl. GST) above benchmark
Benchmark	S&P/ASX Small Ordinaries Accumulation Index (post management fee & expenses)
Unit pricing, applications and redemptions	Monthly
Eligible investors	Wholesale Investors, as defined in the Corporations Act 2001 (Cth)
Distributions	Annually, post 30-Jun, and at the Trustee's discretion

For further information please contact:

WILLIAM SANDOVER

Chief Investment Officer

ws@baza.capital baza.capital +61 499 776 998

BRAYDEN MCCORMACK

Chief Strategy Officer

bm@baza.capital baza.capital +61 401 025 296

RESPONSIBLE INVESTMENT OVERVIEW

Positive screens (non-exhaustive, up to 25% scale-up)			
Renewable energy	Efficient transport		
Recycling	Sustainable products		
Healthy foods	Healthcare & wellbeing		
Education	Electrification		
Direct investment	Strong diversity policies, reporting and practices		

Negative screens	Threshold
Fossil fuel exploration, development or production	Zero tolerance
Provision of significant services to fossil fuel industry	25%+ of focus or revenue, no investment
Excessive carbon emissions	Zero tolerance if no transition, management or offset plans or processes
Gambling or tobacco	Zero tolerance
Old growth logging, destruction of ecosystems or animal cruelty	Zero tolerance
Military technology or armaments	Zero tolerance
Carbon intensive agriculture	25%+ of focus or revenue, no investment

The Fund investigates the diversity of Boards and senior management, and policies and reporting relating to diversity, prior to investment.

Further information on responsible investment policies can be found in the Baza High Conviction Fund Information Memorandum, available by request.

Disclaimer: This report has been prepared by Baza Capital Holdings Pty Ltd (ABN 70 660 169 595) as the fund manager of the Baza High Conviction Fund (ABN 75 493 908 548). True Oak Investments Ltd (ACN 002 558 956 AFSL 238 184) acts as the trustee of the Fund. The Trustee has authorised Baza Capital under its Australian Financial Services Licence (Authorised Representative No. 001297482) to provide general advice and deal in the investments of the Fund. The Fund is an unregistered managed investment scheme. This document contains information about the performance of the Fund and is intended only for investors that are wholesale clients as defined in \$761G of the Corporations Act 2001 (Cth). It is not intended to be used by any other persons in any other jurisdiction if and to the extent that to do so would be in breach of Australian laws, or the laws of any foreign jurisdiction. This report contains general information only and is not intended to provide any person with financial advice. It does not take into account any person's (or class of persons) investment objectives, financial situation or particular needs, and should not be used as the basis for making an investment in the Fund. Neither Baza Capital nor True Oak Investments make any representation as to the accuracy, completeness, relevance or suitability of the information, conclusions, recommendations or opinions contained in this report (including, but not limited to any forecasts made). No liability is accepted by any of these entities or their respective directors, officers, employees, agents or advisors for any such information, conclusions, recommendations or opinions to the fullest extent possible under applicable laws. This publication may contain forward looking statements regarding our intent, belief or current expectations with respect to market conditions. Readers are cautioned not to place undue reliance on these forward-looking statements. The Investment Manager does not undertake any obligation to revise any forward-looking statements to reflect events and circumstances after the date of this publication. Neither Baza Capital nor True Oak Investments guarantee the repayment of capital, the performance of any investment or the rate of return for the Fund. Past performance is not necessarily indicative of future performance. This document is not an Information Memorandum for the purposes of the Act. Accordingly, it does not purport to contain all information that potential investors may need to make an informed assessment as to whether or not to invest in the Fund. Numerical figures in this publication have been subject to rounding.